CN1203864C - Spray formulation of providone iodine - Google Patents
Spray formulation of providone iodine Download PDFInfo
- Publication number
- CN1203864C CN1203864C CN03131706.5A CN03131706A CN1203864C CN 1203864 C CN1203864 C CN 1203864C CN 03131706 A CN03131706 A CN 03131706A CN 1203864 C CN1203864 C CN 1203864C
- Authority
- CN
- China
- Prior art keywords
- iodine
- povidone
- spray
- reddish brown
- brown liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种聚维酮碘的喷雾剂,其特征是含活性剂聚维酮碘、碘酸钾和/或碘化钾、甘油和/或丙二醇、矫味剂和水,其不仅质量稳定,而且对皮肤和粘摸无刺激性,适合经口腔使用,用于防治细菌、真菌和病毒感染。The invention discloses a povidone-iodine spray, which is characterized in that it contains active agents povidone-iodine, potassium iodate and/or potassium iodide, glycerin and/or propylene glycol, flavoring agents and water. It not only has stable quality, Moreover, it is non-irritating to the skin and sticky touch, and is suitable for oral use to prevent and treat bacterial, fungal and viral infections.
Description
一、技术领域1. Technical field
本发明涉及药物制剂领域,具体说是一种含聚维酮碘的喷雾剂。The invention relates to the field of pharmaceutical preparations, in particular to a spray containing povidone-iodine.
二、技术背景2. Technical background
目前我国口腔疾病及咽喉炎的用药状况大致为:口腔外科(如拔牙、牙齿矫型等)一般均以抗生素来预防创面感染,效果好,但属全身用药,不为最合理用药。口腔内科,如口腔溃疡等炎症治疗,以局部用消炎类药物为主,但缺少疗效理想的局部用药物。对于咽喉部位的各类感染也多以口服消炎抗菌类药为主要治疗方法。At present, the medication status of oral diseases and pharyngitis in our country is roughly as follows: oral surgery (such as tooth extraction, tooth correction, etc.) generally uses antibiotics to prevent wound infection, and the effect is good, but it is a systemic medication, which is not the most reasonable medication. Oral medicine, such as the treatment of inflammation such as oral ulcers, is mainly based on topical anti-inflammatory drugs, but there is a lack of topical drugs with ideal curative effect. Oral anti-inflammatory and antibacterial drugs are also used as the main treatment method for various infections of the throat position.
聚维酮碘系碘与聚乙烯吡咯烷酮(PVP)形成的一种可溶性复合物。与碘相比具有水溶性好,挥发性小等优点。是一种广谱,高效,低毒,安全的消毒剂。《中国药典》2000年版已收载聚维酮碘溶液、软膏、栓剂、凝胶等剂型,使聚维酮碘在临床上得以广泛应用。但目前尚缺少适合口腔使用的剂型。Povidone iodine is a soluble complex formed by iodine and polyvinylpyrrolidone (PVP). Compared with iodine, it has the advantages of good water solubility and low volatility. It is a broad-spectrum, high-efficiency, low-toxicity and safe disinfectant. The 2000 edition of "Chinese Pharmacopoeia" has included povidone-iodine solution, ointment, suppository, gel and other dosage forms, so that povidone-iodine can be widely used clinically. However, there is still a lack of dosage forms suitable for oral use.
三、发明内容3. Contents of the invention
本发明的目的是提供一种聚维酮碘的喷雾剂,其不仅刺激性小、安全性好,适合皮肤、特别适合口腔和咽喉部使用,而且质量稳定,能作为药物生产和使用。The object of the present invention is to provide a povidone-iodine spray, which not only has little irritation, good safety, is suitable for the skin, especially for oral cavity and throat, and has stable quality and can be produced and used as medicine.
以下是本发明的详细内容:Below is the detailed content of the present invention:
本发明的聚维酮碘喷雾剂,含以下重量百分比的组分:Povidone-iodine spray of the present invention contains the following components by weight percentage:
聚维酮碘 2-10%Povidone-iodine 2-10%
碘酸钾和/或碘化钾 0.05-2.5%Potassium iodate and/or potassium iodide 0.05-2.5%
甘油和/或丙二醇 5-60%Glycerin and/or Propylene Glycol 5-60%
矫味剂 0.1-3%Flavoring agent 0.1-3%
余量为水The balance is water
其中还可进一步含有0.1-2%的吐温-80。It can further contain 0.1-2% Tween-80.
矫味剂优选薄荷脑和/或巧克力香精。The flavoring agent is preferably menthol and/or chocolate essence.
本发明的喷雾剂,优选的配方如下:Spray of the present invention, preferred formula is as follows:
聚维酮碘 50gPovidone-iodine 50g
碘酸钾 1gPotassium iodate 1g
碘化钾 1.5gPotassium iodide 1.5g
甘油 200mlGlycerin 200ml
丙二醇 100mlPropylene Glycol 100ml
吐温-80 1gTween-80 1g
薄荷脑 2gMenthol 2g
水 加至1000mlAdd water to 1000ml
聚维酮碘系碘与聚乙烯吡咯烷酮形成的一种可溶性复合物。与碘相比具有水溶性好,挥发性小等优点。但是聚维酮碘在贮存过程中有效碘会逐渐分解,在制剂中需要加入一定的稳定剂才能使制剂质量稳定,并且所制备的制剂必须无刺激性或刺激性极小。Povidone-iodine is a soluble complex of iodine and polyvinylpyrrolidone. Compared with iodine, it has the advantages of good water solubility and low volatility. However, the available iodine of povidone-iodine will gradually decompose during storage, and certain stabilizers need to be added in the preparation to make the quality of the preparation stable, and the prepared preparation must be non-irritating or extremely small.
本发明中碘酸钾可作为稳定性,它是一种强氧化剂,使游离碘的还原物碘负离子氧化成碘,而保持杀菌活力。Potassium iodate can be used as a stabilizer in the present invention, and it is a kind of strong oxidizing agent, makes the reduction product iodine negative ion of free iodine be oxidized into iodine, and keeps bactericidal activity.
碘化钾可与碘形成可溶性络合物,而起到助溶作用,并使碘稳定,不易挥发。且络合反应是可逆的,故仍能保持碘的杀菌力。Potassium iodide can form a soluble complex with iodine to help dissolve and stabilize iodine from volatilization. And the complexation reaction is reversible, so the bactericidal power of iodine can still be maintained.
甘油:作为甜味剂;亦可作为碘的溶剂,可缓和碘的刺激性;且易附着于皮肤或粘膜上,使药物滞留患处,而起延效作用。Glycerin: As a sweetener; it can also be used as a solvent for iodine, which can alleviate the irritation of iodine; and it is easy to adhere to the skin or mucous membrane, so that the drug stays in the affected area and plays a prolonging effect.
丙二醇:是良好的分散剂,并具有合适的粘度。Propylene Glycol: It is a good dispersant and has a suitable viscosity.
巧克力香精:可掩盖碘的异味。Chocolate essence: can mask the peculiar smell of iodine.
薄荷脑:聚维酮碘溶液除了具有碘的异臭外,还味苦。薄荷脑的局麻作用对苦味的掩蔽也有效,因此也可用薄荷脑进行矫味。Menthol: In addition to the peculiar smell of iodine, povidone-iodine solution also has a bitter taste. The local anesthetic effect of menthol is also effective in masking the bitter taste, so menthol can also be used for flavoring.
吐温-80:增加分散度。Tween-80: Increases dispersion.
本配方中通过加入碘酸钾、碘化钾使活性成分聚维酮碘稳定,加入甘油、丙二醇、吐温-80作为分散剂和助溶剂,可提高给药部位的吸收速度和吸收量,加入矫味剂可掩盖异味,使患者更易接受,增加了用药顺从性。In this formula, potassium iodate and potassium iodide are added to stabilize the active ingredient povidone iodine, and glycerin, propylene glycol, and Tween-80 are added as dispersants and cosolvents, which can improve the absorption rate and absorption amount of the administration site. Agents can mask odors, making them more acceptable to patients and increasing medication compliance.
本发明喷雾剂的制备方法如下:The preparation method of spray of the present invention is as follows:
将聚维酮碘用1/3水量搅匀、溶解,得到溶液I。将甘油和/或丙二醇和1/3水量混合搅匀,得到溶液II。将溶液I与溶液II合并搅拌均匀得溶液III。另将碘化钾、碘酸钾分别用少量水溶解后加入,搅拌至均匀,加入吐温-80、矫味剂,并加水至总量,搅匀。装入带喷嘴的容器中即成。使用时只要轻轻一喷,药液就均匀地分布在皮肤或粘膜表面,并迅速吸收,达到治疗效果。Stir and dissolve povidone-iodine with 1/3 of water to obtain solution I. Mix and stir glycerin and/or propylene glycol and 1/3 water to obtain solution II. Combine solution I and solution II and stir to obtain solution III. Separately dissolve potassium iodide and potassium iodate with a small amount of water and add, stir until uniform, add Tween-80, flavoring agent, add water to the total amount, and stir well. Serve in a container with a spout. When using it, just spray it lightly, and the liquid medicine will be evenly distributed on the surface of the skin or mucous membrane, and absorbed quickly to achieve the therapeutic effect.
利用本发明的配方和制备方法制备的喷雾剂贮存稳定,以下是部分稳定性试验结果:Utilize the formulation of the present invention and the spray preparation of preparation method to be stable in storage, following are some stability test results:
(一)、试验依据:中国药典2000年版二部(1), test basis: Chinese Pharmacopoeia 2000 edition two
(二)、样品及批号:聚维酮碘喷雾剂,含量10%,批号:000918,000920,000925。(2), sample and batch number: povidone iodine spray, content 10%, batch number: 000918, 000920, 000925.
(三)、检测项目和检测方法:(3), testing items and testing methods:
性状:目视检查。Properties: visual inspection.
pH值:按中国药典2000年版二部附录VIH pH测定法规定测定。pH value: Measured according to the provisions of the Chinese Pharmacopoeia 2000 edition two appendix VIH pH determination method.
含量:按中国药典2000年版聚维酮碘溶液含量测定法测定。Content: determined according to the Chinese Pharmacopoeia 2000 edition povidone-iodine solution content determination method.
(四)、试验结果:(4) Test results:
1、加速试验结果见表1。1. The accelerated test results are shown in Table 1.
2、长期试验结果见表2。2. See Table 2 for the long-term test results.
(五)、结论:按照中国药典2000年版二部进行稳定性试验和含量测定,质量符合规定。(5), conclusion: carry out stability test and content determination according to Chinese Pharmacopoeia 2000 edition two twos, quality accords with the regulation.
表1 聚维酮碘喷雾剂稳定性加速试验(30℃)结果
表2 聚维酮碘喷雾剂室温留样观察试验结果
本发明的另一个优点是所制备的喷雾剂安全、刺激性小,适合用于皮肤,特别适合用于粘膜和咽喉部使用,无毒副作用。Another advantage of the invention is that the prepared spray is safe, less irritating, suitable for use on skin, especially for mucous membrane and throat, and has no toxic and side effects.
以下是本发明喷雾剂的部分药理学研究数据:Below is the part pharmacology research data of spray of the present invention:
一、聚维酮碘喷雾剂口腔给药急性毒性试验1. Acute toxicity test of povidone-iodine spray oral administration
摘要Summary
聚维酮碘喷雾剂家兔口腔给药4小时,剂量按体表面积计算,约为人临床用剂量的51.1倍,未对家兔产生明显毒性作用,7天后家兔无一死亡。LD50大于3.8ml/kg。Povidone-iodine spray was administered orally to rabbits for 4 hours, and the dose was calculated on the basis of body surface area, which was about 51.1 times that of human clinical use. It did not produce obvious toxic effects on rabbits, and none of the rabbits died after 7 days. LD50 is greater than 3.8ml/kg.
(一).试验目的:(1). Purpose of the test:
观察受试物给予家兔后所产生的毒性反应和死亡情况。To observe the toxic reaction and death after the test substance was administered to rabbits.
(二).试验材料:(2). Test materials:
1.受试物:1. Test substance:
本发明聚维酮碘喷雾剂;Povidone-iodine spray of the present invention;
聚维酮碘喷雾剂赋形剂。Povidone-iodine spray excipient.
3.试验动物:3. Test animals:
新西兰大白兔,体重2.5kg左右,雌雄各半。New Zealand white rabbits weigh about 2.5kg, half male and half male.
(三).试验方法:(3). Test method:
1.剂量的选择:选择大于临床50倍的剂量,3.8ml/kg。1. Selection of dose: choose a dose 50 times greater than the clinical dose, 3.8ml/kg.
2.试验方法:取上述家兔12只,随机分为3组,每组4只家兔,雌雄各半,所分3组分别为聚维酮碘喷雾剂剂量组,赋形剂组和空白对照组。聚维酮碘喷雾剂剂量组和赋形剂组给药时,将家兔嘴撑开,把喷雾口对准家兔口腔,分别喷雾入药品,每次喷雾3下,每隔10分钟喷雾一次,在4小时内共喷雾24次,即给药总体积约为3.80ml/kg左右。给药后即刻观察,连续观察7天,记录家兔全身状况,体重、呼吸、循环、中枢神经系统、四肢活动等变化,若出现死亡则应做病理组织学检查。2. Test method: Take 12 above-mentioned rabbits and divide them into 3 groups at random, with 4 rabbits in each group, half male and half male. The three groups are povidone-iodine spray dosage group, vehicle group and blank group respectively. control group. When administering the povidone-iodine spray dosage group and the excipient group, open the mouth of the rabbit, aim the spray port at the mouth of the rabbit, and spray the medicine respectively, 3 sprays each time, once every 10 minutes , A total of 24 sprays within 4 hours, that is, the total volume of administration is about 3.80ml/kg. Immediately after administration, observe for 7 consecutive days, record the rabbit's general condition, changes in body weight, respiration, circulation, central nervous system, limb activities, etc. If death occurs, histopathological examination should be done.
(四).试验结果:(4). Test results:
给药后家兔体重增加,呼吸、循环、中枢神经系统、四肢活动等无明显变化,七天后聚维酮碘喷雾剂剂量组,赋形剂组和空白对照组家兔均无一死亡。After administration, the body weight of the rabbits increased, and there was no significant change in breathing, circulation, central nervous system, and limb activities. Seven days later, none of the rabbits in the povidone-iodine spray group, the vehicle group, and the blank control group died.
(五).试验结论(5). Test conclusion
聚维酮碘喷雾剂家兔口腔给药,未对家兔产生明显毒性作用,LD50大于3.80ml/kg。Oral administration of povidone-iodine spray to rabbits did not produce obvious toxic effects on rabbits, and the LD50 was greater than 3.80ml/kg.
附表:聚维酮碘喷雾剂口腔大剂量给药后家兔体重、呼吸、心跳变化情况:Attached table: Changes in body weight, respiration, and heartbeat of rabbits after oral administration of povidone-iodine spray in large doses:
注:本表家兔给药后第三天,第七天体重、呼吸、心跳变化情况经与给药前比较,未见明显差异。Note: The changes in body weight, respiration, and heartbeat of the rabbits in this table on the third day and the seventh day after administration were compared with those before administration, and there was no significant difference.
参考文献:新药(西药)临床前研究指导原则汇编(药学药理学毒理学)P219-220页References: Compendium of Guiding Principles for Preclinical Research of New Drugs (Western Medicine) (Pharmacy Pharmacology Toxicology) P219-220
二、聚维酮碘喷雾剂口腔给药刺激试验2. Povidone-iodine spray oral administration stimulation test
摘要Summary
聚维酮碘喷雾剂家兔口腔给药4小时,剂量按体表面积计算,约为人临床用剂量的24.77倍,未对家兔产生明显刺激作用。Povidone-iodine spray was administered orally to rabbits for 4 hours, and the dose was calculated on the basis of body surface area, which was about 24.77 times that of human clinical use, and did not produce significant stimulation to rabbits.
(一).试验目的:(1). Purpose of the test:
观察受试物给予家兔后所产生的刺激反应情况。Observe the stimulation response of the test substance given to rabbits.
(二).试验材料:(2). Test materials:
1、受试物:本发明聚维酮碘喷雾剂,批号:000925。1. Test substance: Povidone-iodine spray of the present invention, batch number: 000925.
2.对照品:聚维酮碘喷雾剂赋形剂。2. Reference substance: Povidone-iodine spray excipient.
3.试验动物:新西兰大白兔,体重2.5kg左右,雌雄兼用。3. Experimental animals: New Zealand white rabbits, weighing about 2.5kg, both male and female.
(三)试验方法:(3) Test method:
取上述家兔9只,随机分为3组,每组3只家兔,雌雄兼用,所分3组分别为聚维酮碘喷雾剂剂量组,赋形剂组和空白对照组。The 9 rabbits mentioned above were randomly divided into 3 groups, 3 rabbits in each group, both male and female, and the 3 groups were divided into povidone-iodine spray dose group, vehicle group and blank control group.
聚维酮碘喷雾剂剂量组和赋形剂组给药时,将家兔嘴撑开,把喷雾口对准家兔口腔,分别喷雾入药品,每次喷雾3下,每隔20分钟喷雾1次,在4小时内共喷雾12次,即给药总体积约为1.9ml/kg左右。给药后24小时处死家兔,切开兔嘴,观察口腔粘膜有无充血、红肿等现象,并取面颊部位内的粘膜做组织切片检查。When the povidone-iodine spray dose group and the excipient group were administered, the rabbit's mouth was stretched open, the spray port was aimed at the rabbit's oral cavity, and the medicine was sprayed respectively, 3 sprays each time, and 1 spray every 20 minutes. times, a total of 12 sprays within 4 hours, that is, the total volume of administration is about 1.9ml/kg. The rabbits were executed 24 hours after the administration, and the rabbit's mouth was cut open to observe whether the oral mucosa was congested, red and swollen, etc., and the mucosa in the cheek was taken for tissue section examination.
(四).试验结果:(4). Test results:
给药后24小时解剖家兔,聚维酮碘喷雾剂剂量组,赋形剂组和空白对照组家兔口腔粘膜均未见有充血、红肿等现象。The rabbits were dissected 24 hours after the administration, and the oral mucosa of the rabbits in the povidone-iodine spray group, the vehicle group and the blank control group had no hyperemia, redness and swelling.
(五).试验结论(5). Test conclusion
聚维酮碘喷雾剂家兔口腔给药,未对家兔口腔粘膜产生刺激作用。计量按体表面积折算,约为人临床用剂量的24.77倍。Oral administration of povidone-iodine spray to rabbits did not stimulate the oral mucosa of rabbits. The measurement is converted according to the body surface area, which is about 24.77 times of the human clinical dosage.
参考文献:新药(西药)临床前研究指导原则汇编(药学 药理学毒理学)P220页References: Compendium of Guiding Principles for Preclinical Research of New Drugs (Western Medicine) (Pharmacy Pharmacology Toxicology) P220
三、聚维酮碘喷雾剂小鼠口服给药急性毒性试验3. Oral administration of povidone-iodine spray to mice for acute toxicity test
摘要Summary
聚维酮碘喷雾剂小鼠灌胃一次给药的最大剂量为40ml/kg。The maximum dose of povidone-iodine spray mice administered once is 40ml/kg.
(一).试验目的:(1). Purpose of the test:
观察受试物一次给予小鼠后所产生的毒性反应和死亡情况。Observe the toxic reaction and death after the test substance is given to the mice once.
(二).试验材料:(2). Test materials:
1.受试物:本发明聚维酮碘喷雾剂,批号:000925。1. Tested substance: Povidone-iodine spray of the present invention, batch number: 000925.
2.试验动物:昆明种小白鼠,体重19g-21g左右,雌雄各半。2. Experimental animals: Kunming white mice, weighing about 19g-21g, male and female.
(三).试验方法:(3). Test method:
取本品,经预试验后,取上述小鼠20只,雌雄各半,按聚维酮碘喷雾剂原液一次灌胃给药,0.8ml/20g,即剂量为40ml/kg。给药后即刻观察,连续观察7天,记录小鼠毒性反应和死亡情况,如有死亡,应及时进行尸检,如有肉眼可见病变,则应做病理组织学检查。Get this product, after the preliminary test, get the above-mentioned 20 mice, half male and half male, and give it to the stomach once by povidone iodine spray stock solution, 0.8ml/20g, that is, the dose is 40ml/kg. Immediately after administration, observe for 7 consecutive days, and record the toxicity and death of the mice. If there is death, an autopsy should be carried out in time. If there are lesions visible to the naked eye, histopathological examination should be done.
(四).试验结果:(4). Test results:
给药后小鼠无明显异常反应,七天后小鼠无一死亡。There was no obvious abnormal reaction in the mice after administration, and none of the mice died seven days later.
(五).试验结论(5). Test conclusion
聚维酮碘喷雾剂小鼠一次灌胃给药的最大剂量为40ml/kg。按体表面积折算,约为人临床用剂量的195.5倍。The maximum dose of povidone-iodine spray mice once intragastric administration is 40ml/kg. Converted according to the body surface area, it is about 195.5 times of the human clinical dose.
参考文献:新药(西药)临床前研究指导原则汇编(药学 药理学毒理学)P.198-199References: Compendium of Guiding Principles for Preclinical Research of New Drugs (Western Medicine) (Pharmacy Pharmacology Toxicology) P.198-199
四、具体实施方式:Fourth, the specific implementation method:
实施例1Example 1
聚维酮碘 50gPovidone-iodine 50g
碘酸钾 1gPotassium iodate 1g
碘化钾 1.5gPotassium iodide 1.5g
甘油 200mlGlycerin 200ml
丙二醇 100mlPropylene Glycol 100ml
吐温-80 1gTween-80 1g
薄荷脑 2gMenthol 2g
水 加至1000mlAdd water to 1000ml
将聚维酮碘用1/3水量搅匀、溶解,得到溶液I。将甘油和/或丙二醇和1/3水量混合搅匀,得到溶液II。将溶液I与溶液II合并搅拌均匀得溶液III。另将碘化钾、碘酸钾分别用少量水溶解后加入,搅拌至均匀,加入吐温-80、薄荷脑、巧克力香精,并加水至总量,搅匀。装入带喷嘴的容器中即成。Stir and dissolve povidone-iodine with 1/3 of water to obtain solution I. Mix and stir glycerin and/or propylene glycol and 1/3 water to obtain solution II. Combine solution I and solution II and stir to obtain solution III. Separately dissolve potassium iodide and potassium iodate with a small amount of water and add, stir until uniform, add Tween-80, menthol, chocolate essence, add water to the total amount, and stir well. Serve in a container with a spout.
实施例2Example 2
聚维酮碘 50gPovidone-iodine 50g
碘酸钾 1gPotassium iodate 1g
甘油 300mlGlycerin 300ml
吐温-80 1gTween-80 1g
薄荷脑 2gMenthol 2g
巧克力香精 10g ,
水 加至1000mlAdd water to 1000ml
制备方法同实施例1。The preparation method is the same as in Example 1.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03131706.5A CN1203864C (en) | 2003-07-23 | 2003-07-23 | Spray formulation of providone iodine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03131706.5A CN1203864C (en) | 2003-07-23 | 2003-07-23 | Spray formulation of providone iodine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1481812A CN1481812A (en) | 2004-03-17 |
| CN1203864C true CN1203864C (en) | 2005-06-01 |
Family
ID=34153834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN03131706.5A Expired - Fee Related CN1203864C (en) | 2003-07-23 | 2003-07-23 | Spray formulation of providone iodine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1203864C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021248196A1 (en) * | 2020-06-10 | 2021-12-16 | Firebrick Pharma Limited | Improved virucidal formulations |
| US11246887B2 (en) | 2019-06-10 | 2022-02-15 | Firebrick Pharma Limited | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes |
| AU2021203846B2 (en) * | 2021-06-10 | 2022-11-24 | Firebrick Pharma Limited | Virucidal formulations containing povidone-iodine |
| WO2023053137A1 (en) * | 2021-09-28 | 2023-04-06 | Kejriwal Anil | Molecular iodine, alcohol, and propanediol based formulation and its application for relieving body odor |
| WO2023119321A1 (en) * | 2021-12-20 | 2023-06-29 | Kejriwal Anil | Molecular iodine and propanediol based formulation and its application in oral mucosal and intranasal antisepsis |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299696C (en) * | 2005-07-25 | 2007-02-14 | 华中农业大学 | Povidone iodine effervescence tablet for treating milk cow colpitis, its preparation process and application |
| CN102125053B (en) * | 2011-01-07 | 2013-08-07 | 上海宇昂水性新材料科技股份有限公司 | High-stability non-ionic N-vinyl butyrate lactam iodine solution and related preparation method |
| CN102429921A (en) * | 2011-04-06 | 2012-05-02 | 保全福 | Breast protection film (cow nipple protective agent) |
| CN102379893A (en) * | 2011-08-29 | 2012-03-21 | 江苏德达医药科技有限公司 | Compound pharmaceutical composition of iodine polymer and glucocorticosteroid for treating dermatitis |
| CN102631317B (en) * | 2012-05-03 | 2013-08-28 | 深圳市安多福动物药业有限公司 | Povidone-iodine oral liquid and method for producing same |
| CN102919269A (en) * | 2012-11-02 | 2013-02-13 | 青岛康地恩药业股份有限公司 | Povidone-iodine disinfectant and preparation method thereof |
| CN102949338A (en) * | 2012-11-17 | 2013-03-06 | 河南省康星药业有限公司 | 5% povidone-iodine solution for dairy cattle with strong stability and preparation process thereof |
| CN102961327A (en) * | 2012-12-11 | 2013-03-13 | 河南省康星药业股份有限公司 | Strong-stability 10% povidone-iodine solution for cows and preparation process thereof |
| CN102973601A (en) * | 2012-12-26 | 2013-03-20 | 哈尔滨五牛生物技术开发有限公司 | Medicated bath film forming agent for preventing bouine mastitis and preparation method of medicated bath film forming agent |
| CN103720713B (en) * | 2013-12-18 | 2016-04-20 | 深圳市安多福消毒高科技股份有限公司 | A kind of high chelated iodine and preparation method thereof |
| CN104069070A (en) * | 2014-06-27 | 2014-10-01 | 深圳市格易通消毒药械科技有限公司 | Povidone-iodine powder with effective sterilization and disinfection effects and preparation method thereof |
| CN105694025A (en) * | 2014-11-24 | 2016-06-22 | 天津博克尼科技发展有限公司 | Preparation method of glyceryl polyether and iodine complex |
| CN104906132B (en) * | 2015-06-11 | 2018-11-16 | 青岛农业大学 | A kind of plaster for preventing and treating lamb stomatitis |
| CN106701335A (en) * | 2015-11-14 | 2017-05-24 | 中山市大田汽车护理用品有限公司 | Air conditioning detergent and preparing method thereof |
| CN105412012A (en) * | 2015-12-15 | 2016-03-23 | 张荣华 | Spray for treating chronic pharyngitis |
| CN108670948A (en) * | 2018-05-04 | 2018-10-19 | 江西新天地药业有限公司 | A kind of nanoscale micro-capsule unimolecule Betagen Solution and preparation method thereof |
| CN108653201B (en) * | 2018-06-11 | 2021-05-14 | 佛山市南海东方澳龙制药有限公司 | Drip-proof povidone iodine solution and preparation method thereof |
| CN110037940A (en) * | 2019-05-22 | 2019-07-23 | 浙江欧洁科技股份有限公司 | A kind of sterilizing oral disinfection mouthwash and preparation method thereof and application method |
| CN111956613A (en) * | 2020-09-30 | 2020-11-20 | 厦门汇承药业有限公司 | Preparation method of animal wound treatment spray |
| CN114259503A (en) * | 2021-12-28 | 2022-04-01 | 厦门海强生科技有限公司 | Povidone-iodine solution for human and preparation method thereof |
| CN116531328A (en) * | 2023-05-11 | 2023-08-04 | 湖北凤凰白云山药业有限公司 | Preparation method of povidone-iodine chrysanthemum spray |
-
2003
- 2003-07-23 CN CN03131706.5A patent/CN1203864C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246887B2 (en) | 2019-06-10 | 2022-02-15 | Firebrick Pharma Limited | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes |
| US11969441B2 (en) | 2019-06-10 | 2024-04-30 | Firebrick Pharma Limited | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes |
| WO2021248196A1 (en) * | 2020-06-10 | 2021-12-16 | Firebrick Pharma Limited | Improved virucidal formulations |
| AU2021203846B2 (en) * | 2021-06-10 | 2022-11-24 | Firebrick Pharma Limited | Virucidal formulations containing povidone-iodine |
| WO2023053137A1 (en) * | 2021-09-28 | 2023-04-06 | Kejriwal Anil | Molecular iodine, alcohol, and propanediol based formulation and its application for relieving body odor |
| WO2023119321A1 (en) * | 2021-12-20 | 2023-06-29 | Kejriwal Anil | Molecular iodine and propanediol based formulation and its application in oral mucosal and intranasal antisepsis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1481812A (en) | 2004-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1203864C (en) | Spray formulation of providone iodine | |
| CN1307971C (en) | Antimycotic nail varnish composition | |
| CN1311628A (en) | Methods and compositions for treating skin allergies and infections | |
| CN101444555B (en) | A kind of pure Chinese medicinal film for treating oral ulcer and preparation method thereof | |
| CN105342987A (en) | Gel as well as preparation method and application thereof | |
| JPH01503146A (en) | Methods of treating body tissue and administering medicines to body tissue | |
| CN1316965C (en) | A transparent and invisible external drug delivery carrier | |
| CN1224424C (en) | Mucoadsorptive thermosetting pharmaceutical carrier composition | |
| CN1765369A (en) | Nano silver gel and its application | |
| CN1917891A (en) | Medicament on the basis of honey, preparation and use thereof | |
| CN1480128A (en) | Preparation of transparent, cryptomorphic external remedy | |
| CN104758304B (en) | Medicinal use of notoginseng saponin R1 | |
| CN1243437A (en) | Use of dichlorobenzyl alchol for preparing a preparation for topical treatment of inflammation and preparation containing dichlorobenzyl alchol | |
| CN1925841A (en) | Pharmaceutical preparation for the oral cavity | |
| CN1372468A (en) | Oral preparations of etidronate disodium | |
| CN101053657A (en) | External applied preparations for treating intractable skin ulcer | |
| TWI848607B (en) | Use of a hypochlorous acid composition for preparing a pharmaceutical composition for preventing, improving or treating radiation dermatitis | |
| RU2432942C1 (en) | Composition for preparation of medicinal form possessing prolonged action for treatment of oropharyngeal zone | |
| JP2006008540A (en) | Cold remedy | |
| CN106507666A9 (en) | Use of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof for the treatment of sarcoidosis | |
| CN114788821A (en) | Pharmaceutical composition and application thereof | |
| CN1743027A (en) | Silver-contained oral-cavity cleaning article | |
| CN116059327B (en) | A lysozyme nasal spray and preparation method thereof | |
| CN1272012C (en) | Dermatopathy therapeutic medicine compositions and its preparation method | |
| EP2978435B1 (en) | A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |